ME Awareness – Join the WAMES ‘Help NHS be ME aware’ campaign

ME Awareness – Join the WAMES #HelpNHSbeMEaware campaign

 

During ME Awareness week 2017 WAMES is launching a challenge to the Welsh Government and NHS Wales to help NHS staff become ‘ME aware’ by developing awareness and training programmes. Read more

 

Do you wish NHS staff knew more about neurological ME?

Have you had a bad experience because your doctor, nurse, paediatrician etc. didn’t know enough about ME?

 

Let the Health Boards know:

  • Email with the challenge and tell them about your experience. Include the link to the blog post and keep it short!
  • Retweet WAMES #HelpNHSbeMEaware and #BeMEAware and #postexertionalmalaise tweets
  • Tweet the NHS staff you follow with  e.g.
    My GP (or nurse or paediatrician etc.) doesn’t understand neurological ME & #postexertionalmalaise. Please provide training!  #HelpNHSbeMEaware #BeMEaware
  • Please give training about ME and #postexertionalmalaise to NHS staff #HelpNHSbeMEaware  #BeMEaware
  • Repost the WAMES FB post
  • Post to NHS FB sites
  • Write to staff at their HQ address
  • Add a # BeMEaware poster

Contact details:

Cabinet secretary for Health

Vaughan Gething AM Correspondence.Vaughan.Gething@gov.wales twitter:   @wgcs_health           https://www.facebook.com/VaughanGething1/

Betsi Cadwaladr UHB

Hywel Dda  UHB

Powys tHB

Abertawe Bro Morgannwg UHB

Cardiff & Vale UHB

Cwm Taf UHB

Aneurin Bevan UHB

 

Posted in News | Tagged , | 2 Comments

Access to medical care for ME & CFS: a call for centres of excellence in the USA

Research abstract:

Access to Medical Care for Individuals with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: A Call for Centers of Excellence, by Madison Sunnquist, Laura Nicholson, Leonard A Jason, and Kenneth J Friedman in Modern Clinical Medicine Research, Vol. 1, No. 1, April 2017

The current study sought to better understand the experience of individuals with myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) in accessing care for their debilitating illness.

Of 898 participants, less than half had ever seen an ME or CFS specialist, though 99% of participants were interested in specialist care. Participants cited geographic and financial barriers as most frequently precluding access to specialists.

Furthermore, satisfaction with specialist care greatly exceeded satisfaction with non-specialist care.

These findings suggested that individuals with ME and CFS represent a medically-underserved population, due to lack of available care.

The CFS Advisory Committee and NIH Pathways to Prevention Working Group recommended the creation of ME and CFS Centers of Excellence to improve the healthcare access of patients with ME and CFS. The current study documents the need for these centers, as they would ameliorate geographic and financial barriers to quality care.

Posted in News | Tagged , , , , , | Comments Off on Access to medical care for ME & CFS: a call for centres of excellence in the USA

ME Awareness – BeMEaware! 2

Download poster #BeMEaware

Posted in News | Tagged | Comments Off on ME Awareness – BeMEaware! 2

ME Awareness – Be ME Aware!

Download poster #BeMEaware

 

 

Posted in News | Tagged | Comments Off on ME Awareness – Be ME Aware!

ME Awareness – Wear blue for awareness week 2017

ME Awareness week 8-14 May 2017

 

This is the week we tell people about ME. Wearing blue to match our blue ribbons is one of the ways we can attract attention and invite conversations about the debilitating illness that affects an estimated 13,000 people in Wales.

Blue ideas for when you travel out into the local community or onto social networks:

blue hair                                                                                        blue clothes

 

 

 

 

 

 

                    blue nails                                                     blue make-up

 

 

 

 

Posted in News | Tagged , | Comments Off on ME Awareness – Wear blue for awareness week 2017

Vitamin and mineral status in CFS & FM

Review abstract:

Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: a systematic review and meta-analysis, by Monica L Joustra, Isidor Minovic, Karin A M Janssens, Stephan JL Bakker, Judith GM Rosmalen in PLoS ONE 12(4): e0176631 [Published: April 28, 2017]

BACKGROUND

Many chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) patients (35–68%) use nutritional supplements, while it is unclear whether deficiencies in vitamins and minerals contribute to symptoms in these patients. Objectives were (1) to determine vitamin and mineral status in CFS and FMS patients as compared to healthy controls; (2) to investigate the association between vitamin and mineral status and clinical parameters, including symptom severity and quality of life; and (3) to determine the effect of supplementation on clinical parameters.

METHODS

The databases PubMed, EMBASE, Web of Knowledge, and PsycINFO were searched for eligible studies. Articles published from January 1st 1994 for CFS patients and 1990 for FMS patients till March 1st 2017 were included. Articles were included if the status of one or more vitamins or minerals were reported, or an intervention concerning vitamins or minerals was performed. Two reviewers independently extracted data and assessed the risk of bias.

RESULTS

A total of 5 RCTs and 40 observational studies were included in the qualitative synthesis, of which 27 studies were included in the meta-analyses. Circulating concentrations of vitamin E were lower in patients compared to controls (pooled standardized mean difference (SMD): -1.57, 95%CI: -3.09, -0.05; p = .042). However, this difference was not present when restricting the analyses to the subgroup of studies with high quality scores.

Poor study quality and a substantial heterogeneity in most studies was found. No vitamins or minerals have been repeatedly or consistently linked to clinical parameters. In addition, RCTs testing supplements containing these vitamins and/or minerals did not result in clinical improvements.

DISCUSSION

Little evidence was found to support the hypothesis that vitamin and mineral deficiencies play a role in the pathophysiology of CFS and FMS, and that the use of supplements is effective in these patients.

REGISTRATION

Study methods were documented in an international prospective register of systematic reviews (PROSPERO) protocol, registration number: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015032528

Posted in News | Tagged , , | Comments Off on Vitamin and mineral status in CFS & FM

ME Awareness – Light the sky blue!

ME Awareness – light the sky blue on International ME Awareness day 12th May 2017

In recent years a number of public buildings in towns and cities, which are always lit up at night, have switched to blue lights to mark ME Awareness day. This makes a great statement. Do you know a building that could go blue on May 12th this year? Ask them.

Why not use those blue Christmas LED lights to decorate a window, tree or bush outside your house and ask your neighbours to join in.

Ask your local newspaper to run a story on why you are lighting up and/or wearing blue this year.

Blue balloons tied to the gatepost could make a blue statement during the day.

Posted in News | Tagged , | Comments Off on ME Awareness – Light the sky blue!

The role of cytokine IP-10 in CFS

Research Abstract:

The role of IP-10 in Chronic Fatigue Syndrome, by Anne McArdle, Arief Gusnanto, Kate Ear, George Sakellariou, Clare Lawton, Daniel Owens, Graeme Close, Michael Beadsworth, Louise Dye in FASEB Journal Vol. 31:1 Supplement, lb789  April 2017

Chronic fatigue syndrome (CFS) is a severely debilitating and complex illness of uncertain cause, characterised by prolonged, fatigue triggered by minimal activity. There is evidence that CFS is associated with chronic inflammation. Studies have shown that plasma levels of cytokines are chronically modified in patients with CFS.

This study examined physiological, subjective and cognitive factors associated with plasma cytokine concentrations in a cohort of 92 patients compared with age and sex matched healthy controls. A sub-group of patients and healthy controls (HCs) also underwent more detailed analyses of muscle function, cytokine production and cognitive function.

Patients were diagnosed with CFS if they met the Oxford criteria for Chronic Fatigue  Syndrome and recommended NICE guidelines. Patients completed a number of validated questionnaires including the Chalder Fatigue Questionnaire (CFQ) which is considered a valid and reliable measure of fatigue in patients with CFS.

Patients with CFS demonstrated a characteristic significant reduction in Maximal Voluntary Contraction Force compared with HCs. Data on plasma concentrations of 27 pro- and anti-inflammatory cytokines were analysed using multiple or logistic regression with age and sex which were significant covariates included in each model.

CFS was strongly associated with a limited number of cytokines. Diagnosis of CFS was  associated with increased plasma contents of MIP-1a, MIP-1b and RANTES (p<0.05) and marginally with Eotaxin (p=0.07) when modelled individually. MVC and self-reported fatigue both showed particularly strong associations with plasma IP-10 concentrations. Muscle content of IP-10 mRNA was significantly elevated, suggesting that, at least in part, muscle was a source of this IP-10 but not the other cytokines.

Pairwise associations between MVC and cytokines demonstrated that the reduced MVC seen in patients with CFS was strongly associated with plasma levels of IP-10, TNF-alpha and IL-5. Further analyses revealed strong correlations between plasma RANTES and eotaxin levels and poorer verbal recall and RTs of patients with CFS. The consistent association of IP-10 with the physiological features and of RANTES and eotaxin with the cognitive features of CFS provides compelling evidence for a role of these cytokine/ chemokines in the physiological and cognitive pathology of CFS.

This work was funded by the Medical Research Council.

Posted in News | Tagged , , | Comments Off on The role of cytokine IP-10 in CFS

ME awareness – wear, post or tweet a blue ribbon

Wear a blue ribbon on May 12th, International ME Awareness Day, whenever you go out, post or tweet

blue ribbon photoThe charity BRAME (Blue Ribbon Awareness for ME) sells blue ribbons as a triple symbol of hope for all those affected by ME/CFS:

It is creating awareness of ME/CFS

It is helping to raise funds for research

   It is showing support for those affected by ME/CFS

  • 5p per ribbon plus 50p P&P on orders up to £5
  • £1.50 per BRAME enamel badge plus 50p P&P on orders up to £5
  • Order from: BRAME
    30 Winmer Avenue, Winterton-on-Sea, Great Yarmouth, Norfolk,
    NR29 4BA    Tel/Fax: 01493 393717   info@brame.org

Download a WAMES twibbon to add to your twitter or FB page and show your support for ME in Wales

 

Posted in News | Tagged , , | Comments Off on ME awareness – wear, post or tweet a blue ribbon

PLOSone journal ‘expression of concern’ about PACE authors’ unwillingness to share data

Expression of Concern: Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis, by the PLOS ONE Editors in PLoS ONE 12(5)e0177037 [Published: May 2, 2017]

Several readers have raised concerns about some of the analyses reported in the article and made requests for the data underlying this study.

The PLOS ONE policy governing the sharing of data that applies to articles submitted before March 3, 2014, requires that authors agree to make freely available any materials and data described in their publication that may be reasonably requested for the purpose of academic, non-commercial research (http://journals.plos.org/plosone/s/file?id=c4aa/PLOSONE_data_policy_before_2014March.pdf).

We assessed the concerns raised and the requests for data and we sought advice from two editorial board members. The advice we received was that the individual-level patient data for Tables 1,2,3,4 and 5 are necessary to replicate the cost-effectiveness analyses reported in the article. In line with the advice received, we contacted the authors to request the individual-level patient data for these tables.

The authors raised concerns related to patient confidentiality and specifications under the consent sought from participants at the time of recruitment for the trial.

In consideration of the requirements for ethical oversight of data access that may apply to datasets involving human subjects, we contacted the authors and Queen Mary University of London, where the dataset is held, to request that steps be taken to develop a mechanism that would allow requests for data to be independently reviewed and the data released in accordance with our policy while respecting patient privacy. The authors and Queen Mary University of London shared the data policy in place at the institution, however we consider that aspects of the existing framework impose limitations and conditions not aligned with our editorial policy.

The authors have offered to release aggregated data from the study but have reiterated reservations about the public release of individual-level patient data. The journal policy does not require public release of anonymised patient-level data, but does require a suitable framework for data access for the purpose of academic, non-commercial research. While the release of summarized data does not fully comply with the journal requirements, we welcome that the authors are now willing to share summarized data, and we will provide this once it is made available to us.

In spite of requests to the authors and Queen Mary University of London, we have not yet received confirmation that an institutional process compatible with the existing PLOS data policy at the time has been developed or implemented for the independent evaluation of requests for data from this study. We conclude that the lack of resolution towards release of the dataset is not in line with the journal’s editorial policy and we are thus issuing this Expression of Concern to alert readers about the concerns raised about this article.

Statement from the authors

We disagree with the Expression of Concern about our health economic paper that PLOS ONE has issued and do not accept that it is justified.

We believe that data should be made available and have shared data from the PACE trial with other researchers previously, in line with our data sharing policy. This is consistent with the data sharing policies of Queen Mary University of London, and the Medical Research Council, which funded the trial. The policy allows for the sharing of data with other researchers, so long as safeguards are agreed regarding confidentiality of the data and consent as specified by the Research Ethics Committee (REC). We have also pointed out to PLOS ONE that our policy includes an independent appeal process, if a request is declined, so this policy is consistent with the journal’s policy when the paper was published.

During negotiations with the journal over these matters, we have sought further guidance from the PACE trial REC. They have advised that public release, even of anonymised data, is not appropriate. As a consequence, we are unable to publish the individual patient data requested by the journal. However, we have offered to provide key summarised data, sufficient to provide an independent re-analysis of our main findings, so long as it is consistent with the REC decision, on the PLOS ONE website. As such we are surprised by and question the decision by the journal to issue this Expression of Concern.

Reference

1. McCrone P, Sharpe M, Chalder T, Knapp M, Johnson AL, Goldsmith KA, et al. (2012) Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis. PLoS ONE 7(8): e40808.

More information about editorial policy:

PLOS one blog post,by Iratxe Puebla and Joerg Heber, 2 May 2017: Data sharing in clinical research: challenges and open opportunities

 

Posted in News | Tagged , , | Comments Off on PLOSone journal ‘expression of concern’ about PACE authors’ unwillingness to share data